Anglo-Swedish drug major AstraZeneca has opened a state-of-the-art process, research and development laboratory next to its established R&D base in Bangalore, India. The new $15.0 million site covers 8,000 square meters and can accommodate 75 process scientists, as well as office support and engineering staff. The firm said that the new PR&D facility would strengthen its existing global process development capacity, and was a further demonstration of its commitment to operations in India.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze